Health & Biotech Diagnosing mental disorder through sleep: How TrivarX could capture this huge research market February 22, 2024 TrivarX's AI technology diagnoses mental health via sleep monitoring. Stockhead reached out to TrivarX's COO, Kai Sun. Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners February 22, 2024 Iron Mike Tyson has spoken out against the jailing of cannabis users. Iron Mike owns his own cannabis brand called… ‘Significant potential’: This ASX stock is winning the race to make cancer care heart-safe February 22, 2024 Race Oncology (ASX:RAC) is working to minimise damage to the heart linked to almost all cancer therapies with its core… Neurotech reports sustained clinical progress in PANDAS/PANS patients during Phase I/II extension study February 22, 2024 Neurotech reports paediatric patients in the PANDAS/PANS Phase I/II clinical trial extension phase continue to show significant improvements between 12… ASX Health Stocks: Sonic slumps after H1 profits fall 47pc. CEO says don’t worry, we’re back to normal now February 20, 2024 Sonic Healthcare's shares dumped after profits decline by half. Singular Health retains ISO certificate for medical device. ASX stocks striving to inject youthfulness into an aging world population February 20, 2024 Anti-aging and longevity has become a focus area for pharmaceutical and biotech companies including on the ASX. Fundie Merchant Group picks four biotech stocks that could rip as sector hits rude health again February 20, 2024 After a testing time post-pandemic boom, biotech has made a strong comeback. Merchant Group's boss gives us his top ASX… ASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pc February 19, 2024 Starpharma suffers setback after US FDA appeal rejected LTR Pharma to commence study on erectile dysfunction nasal spray, SPONTAN … LTR Pharma firms up study for erectile dysfunction with patient recruitment February 19, 2024 LTR Pharma has begun patient recruitment for its clinical study into SPONTAN®, designed to be a world-first, fast acting, on-demand… ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpoint February 16, 2024 The ASX health sector has fallen in the past five days with blood products giant CSL (ASX:CSL) down after Phase… Next» « Previous